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Abstract 
Alignment of previously characterized S-100 (ct and 13)-binding peptides (J. Biol. Chem. 270, 14651-14658) has enabled the 
identification of a putative S-100 target epitope within the head domain of glial fibrillary acidic protein (GFAP). The capacity of a known 
peptide inhibitor of S-100 protein (TRTK-12), homologous to this region, to perturb the interaction of S-100 (ct and 13) and GFAP (J. 
Biol. Chem 268, 12669-12674) was investigated. Fluorescence spectrophotometry and chemical cross-linking analyses determined 
TRTK-12 to disrupt S-100:GFAP interaction in a dose- and Ca2+-dependent manner. TRTK-12 also inhibited S-100's ability to block 
GFAP assembly and to mediate disassembly of preformed glial filaments. Each of these events was strictly dependent upon the presence 
of calcium and inhibitory peptide, maximal inhibition occurring at a concentration f TRTK-12 equivalent to the molar amount of S-100 
monomer present. Together with our recent report demonstrating TRTK-12 also blocks the interaction of S-100 protein with the actin 
capping protein, CapZ, these results suggest TRTK-12 functions as a pleiotropic inhibitor of S-100 function. Availability of a functional 
inhibitor of S-100 will assist the further characterization of S-100 protein function in vitro and in vivo. Moreover, this report provides 
additional evidence supportive of a role for S-100 as a multi-faceted regulator of cytoskeletal integrity. 
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1. Introduction 
S-100 proteins are a subfamily of the EF-hand class of 
Ca2--binding proteins consisting of S-100et, S-10013, and 
a variety of S100-1ike proteins (for reviews see Refs. 
[1-5]). Expression of S-100oL is restricted to cardiomy- 
ocytes, slow-twitch skeletal muscles and kidney tubular 
cells [6-9]. S-10013 is more widely distributed, being 
particularly abundant in glia [10]. While S-100o~ and 
S-10013 localize primarily to the cytoplasm, they also have 
been found associated with membranous fractions and/or  
Abbreviations: GFAP, glial fibrillary acidic protein; GF, glial fila- 
ment; IF, intermediate filament; DTT, dithiothreitol; DSS, disuccininidyl 
suberate; PAGE, polyacrylamide gelelectrophoresis. 
* Corresponding author. Fax: + 39 75 5853451. 
ciliary axonemes, basal bodies, centrioles, submembranous 
cytoskeleton, and intermediate filaments [10-16]. Canoni- 
cal S-100 proteins, (i.e., S-100et and S-I0013) have been 
implicated in the regulation of a variety of intracellular 
activities including: microtubule assembly-disassembly 
([17], and references therein), phosphorylation of specific 
cellular substrates [18-21], adenylate cyclase [22], 
caldesmon's inhibitory activity on actomyosin ATPase ac- 
tivity [21,23], and Ca 2 ÷-induced Ca 2 ÷ release [24]. S- 100 
and S-10013 frequently dimerize, producing the homod- 
imers e~tx (S-100a o) and 1313 (S-100b) as well as the 
heterodimer ~13 (S-100a) [1-5]. S-10013 is released from 
glial cells in the brain [25]. In that non-reducing extracellu- 
lar environment i resides as a disulfide-cross-linked 1313- 
dimer [26] to which both neurotrophic [26-29] and mito- 
genic [30] activities have been attributed. 
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Recently, we [31] have reported the ability of S-100 (a 
and [3) to interact with glial fibrillary acidic protein 
(GFAP), a type III intermediate filament (IF) protein ex- 
pressed within differentiating and mature glial cells [32]. In 
those studies S-100 protein inhibited in a Ca2+-dependent 
fashion the assembly of glial filaments (GFs) [31]. More- 
over, inhibition of assembly, as well as induction of fila- 
ment disassembly, was dependent upon the Ca2+-depen - 
dent association of S-100 protein with unassembled GFAP 
[33]. In addition to inducing disassembly, S-100's associa- 
tion with GFAP increased the critical concentration of 
GFAP required for polymerization and inhibited filament 
elongation [33]. 
Previously we [34] employed Ca2+-dependent affinity 
chromatography to identify S-10013 target epitopes con- 
tained within a library of random sequences. In that study 
a subset of S-100 binding peptides possessing a common 
sequence motif was identified. Further analysis identified a
homologous equence [34] within the carboxy-terminal 
region of the a-subunit of actin capping proteins [35,36]. 
A synthetic peptide spanning the region identified within 
CapZ~l/oL, 265TRTKIDWNKILS276 (TRTK-12), bound 
S-10013 and inhibited the interaction of S-10013 and CapZ 
in a Ca 2+-, dose- and sequence-specific ashion. Essen- 
tially identical observations have been obtained recently 
with S-100a [37]. 
In the current study we sought o identify a molecular 
mechanism for the action of S-100 (e~ and [3) on GFAP. 
Alignment of our S-100-binding peptide sequences with 
the regions known to mediate important aspects of supra- 
molecular assembly of IF proteins - i.e., the head and tail 
domains (for reviews see [38-43]) - enabled us to identify 
a putative S-100 target epitope within the head region of 
GFAP. We then proceeded to examine whether TRTK-12, 
an S-100 inhibitory peptide homologous to the region 
identified, blocked the interaction of S-100 protein and 
GFAP. Specifically, we examined the effect of TRTK-12 
on S-100's binding to GFAP, inhibition of GFAP assem- 
bly, and induction of GF disassembly. 
polymerization i hibition assays, further fractionation was 
not required [31]. GFAP was purified from bovine spinal 
cord as described [45]. TRTK-12 was obtained commer- 
cially. The following molecular weights were applied: 50 
kDa (GFAP); 21 kDa (S-100 dimer); and 1470 Da (TRTK- 
12). 
2.3. Preparation of fluorescently labelled proteins 
S-100 protein was labelled with acrylodan as described 
[46]. Briefly, S-100 protein was incubated at 4°C for 2 h in 
25 mM imidazole-HC1 (pH 7.0), 0.1 M NaCI, 0.2 mM 
EGTA containing 2.5 mM CaC12, with a 5 molar equiva- 
lent of acrylodan, a thiol derivative of Prodan [47]. The 
reaction was terminated by addition of DTT (5 mM final). 
After 30 min EGTA was added (2.5 mM final), uncoupled 
dye removed by gel filtration and the labelling ratio 
(dye/protein) determined (1.8) as described [47]. Acrylo- 
dan-S-100 containing fractions were combined and dia- 
lyzed against 5 mM imidazole-HC1 (pH 7.0), 0.2 mM 
EGTA, 1 mM DTT. GFAP was labelled using a similar 
approach [48]. Briefly, protein was incubated in 5 mM 
imidazole-HC1 (pH 7.0), 8 M urea, 0.2 mM EGTA at room 
temperature for 2 h with 5 molar equivalents of acrylodan. 
The reaction was terminated, uncoupled ye removed and 
the labelling ratio determined to be 0.85, essentially as 
described above. Fractions containing acrylodan-GFAP 
were combined and dialyzed, again as described above. 
2.4. Fluorescent spectrophotometry 
Fluorescent spectrophotometric analyses were per- 
formed in 10 mM imidazole-HC1 (pH 7.0), 1 mM MgC12, 
1 mM DTT, 0.2 mM EGTA plus or minus CaCI 2. Fluores- 
cence emission spectra (excitation: 380 nm; emission: 
400-650 nm) were recorded at 25°C using a Shimadzu 
RF-5000 spectrofluorometer. Emission spectra were cor- 
rected for dilution which never exceeded 5%. 
2.5. Cross-linking experiments 
2. Materials and methods 
2.1. Chemicals 
Acrylodan was obtained from Molecular Probes, disuc- 
cinimidyl suberate (DSS) from Pierce, and dithiothreitol 
(DTT) from Sigma. All other reagents were analytical 
grade reagents from Sigma, Fluka, BDH, Bio-Rad, or 
Carlo Erba. 
2.2. Purification of proteins 
S-100 protein, consisting of = 20% S-100et and = 80% 
S-10013, was purified as described [17,44]. As both iso- 
types possess equivalent activity in GFAP binding and 
S-100 protein was incubated at 22°C for 30 min in 10 
mM imidazole-HC1 (pH 7.4), 1 mM MgC12, 1 mM DTT, 
0.2 mM EGTA plus or minus CaCI 2 (final volume 0.1 ml) 
in the presence of added buffer, GFAP and/or TRTK-12 
prior to addition of the bifunctional cross-linker DSS (final 
concentration 0.5 mM). After incubation for 15 min at 
room temperature, reactions were terminated by addition 
of 2% SDS (w/v)  and 2% 2-mercaptoethanol and samples 
analyzed by SDS-PAGE (10% acrylamide) [49]. Gels were 
stained with Coomassie brilliant blue using standard proce- 
dures. 
2.6. Sedimentation assay 
GFAP was assembled at 22°C for 30 min in 0.1 M 
imidazole-HC1 (pH 6.8), 1 mM DTI', 1 mM MgCIz, = 3 
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IxM free Ca 2+ (final volume 0.1 ml) in the presence of 
added buffer, S-100 protein, and/or TRTK-12 peptide as 
described in the Figure legends. Mixtures were spun in a 
centrifuge at room temperature for 30 min (13000 × g) to 
separate supernatants from pellets. Individual pellets were 
resuspended in 0.1 ml of 5 mM Tris-HC1 (pH 7.0), 0.2 
mM EGTA. Identical volumes of supernatants and pellets 
(20 tzl) were brought to 2% SDS and 2% 2-mercapto- 
ethanol and analyzed by SDS-PAGE (10% acrylamide). 
Subsequent to staining, gels were photographed, the pic- 
tures obtained scanned using a HP LaserJet 5MP and the 
relative proportion of GFAP contained in supernatants and 
pellets determined. Residual material was used in protein 
assays using the method of Lowry et al. [50]. 
2. 7. Viscosity measurements 
The increase in viscosity of samples of GFAP under 
assembly conditions was measured using an Ostwald vis- 
cometer [51] with a sample volume of 0.75 ml and a buffer 
flow time of 50 s at 22°C, otherwise conditions were 
identical to those used in sedimentation assays. The time 
required for the solution to pass through an upper and 
lower mark of the glass capillary tube was measured every 
5 min. Specific viscosity ('qsp) was calculated by the 
equation: "qsp = (t a - tb)/t b, where t b is the flow time of 
the sample before the addition of the assembly buffer (0.1 
M imidazole-HCl, pH 6.8, final concentration) and t a the 
flow time of the sample after the addition of the assembly 
buffer. 
2.8. Other procedures 
Free Ca 2+ concentration was measured by the method 
of Harafujii and Ogawa [52]. 
3. Results 
into two broad categories, homologous to either the 
amino-terminal portion or the carboxy-terminal portion of 
this region. Further analysis determined alignment of many 
members of the amino-terminal group could be extended 
towards the carboxy-region if we took into consideration 
the hexaproline sequence located proximal to the random 
peptide domain of the bacteriophage library from which 
our S-100-binding peptides had been isolated. Alignment 
of selected peptides is presented in Table 1. An integrated 
index of alignment was derived by assigning a score to 
each sequence position based upon whether aligned pep- 
tides were identical, represented conservative replace- 
ments, or possessed similar hydrophobicity/hydrophilic- 
ity. As depicted in Fig. 1 use of this index provides a 
striking graphical representation f the region of interest 
within the head domain. Based upon these observations we 
conclude that this domain contains the site of S-100:GFAP 
interaction. Noteworthy, this domain contains a motif, the 
RP-box, that is located just upstream of the GFAP a-heli- 
cal domain and which has been suggested to play a key 
role in modulating GFAP assembly [56]. 
Table 1 
Sequence alignment of S-100-binding peptides and GFAP head domain 
Peptide 
(i) LFPRSKIS 08 
RLSLDSWL 32 
TVFRMDLLKLLSSMP 30 
SKKLSWDRVLTMMP 09 
PRLPWSFFFSPPP 03 
RLNISHLFPPPP 24 
SSVKLTLRQLFPPPP 25 
LKSPLTWDQVLQSSP 22 
IRKSLPWSLILPPPP 05 
TRFPIPWSLLPPPPP 06 
PLTFLDLSRLYPPPP 16 
(24) LAPGRRLG--PGTRLSLARMPPPLPTRVDFS-LAGALNAG(58)-hu-GFAP 
3.1. Alignment of previously characterized S-lO0-binding 
peptides 
To identify a molecular mechanism for the action of 
S-100 protein on GFAP assembly and disassembly we 
aligned our set of S-100-binding peptides [34] with the 
head and tail domains of GFAP [53], regions demonstrated 
previously to mediate important aspects of supra-molecular 
assembly of IF proteins [38-43]. S-100-binding peptides 
were aligned with GFAP head and tail regions using visual 
inspection and the computer alignment programs BLAST 
[54] and MACAW [55]. A 21 amino-acid segment 
(31PGTRLSLARMPPPLPTRVDFSsl) contained within the 
head domain was identified which exhibited strong homol- 
ogy to our set of S-100-binding peptides. In fact essentially 
all 35 S-100-binding peptides could be aligned, with vary- 
ing degrees of homology, along this segment. Peptides fell 
(ii) 
TRTKIDWNKILS TKIDW TRTK-12 
TTQRLPMRIPEVFSFP 18 
AELPAKLPME 19 
TEPRLPWSFS 03 
PRLST 23 
LSPRIP 04 
SPRLPIELLFA 13 
AGVTSALHQRLNIS 24 
TNVRISL 30 
Conventional single-letter amino-acid code was used. Sequence alignment 
of S-100-binding peptides, TRTK-12 and human GFAP [53] was accom- 
plished using the NCBI program MACAW [54]. Dashes have been 
inserted solely for the purpose of presentation and do not indicate 
position of amino-acid residues. Alignments of representative p ptides 
homologous to the (i) amino-terminal and (ii) carboxy-terminal portion of 
the S-100 target domain identified within the head domain of GFAP are 
presented. The numbers in the peptide column represent those of the 
initial isolate reported in [34]. 
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Fig. 1. Alignment of S-100 (~ and 13)-binding peptides and GFAP head and tail domains, Alignment of S-100-binding peptide sequences to those 
contained within the head and tail domains of human GFAP [53] was accomplished using the NCBI program MACAW [54]. An alignment score was 
calculated as an index of sequence homology as follows; for each segment of S-100-binding peptide placed in alignment with the GFAP head or tail 
domain a score was assigned to the corresponding positions of GFAP based upon whether the aligned peptide residue was identical (4 pts.), represented a 
conservative r placement (2 pts.), or possessed similar hydrophobicity or hydrophilicity (1 pts.). Positional totals were obtained and plotted vs. the 
corresponding GFAP residue position. Panels: head domain (left) and tail domain (right). 
To test this hypothesis we performed a series of studies 
using TRTK-12, a peptide homologous to the region we 
identified within the head domain of GFAP and an effec- 
tive, targeted, high affinity inhibitor of S-100 (a and 13) 
[34,37]. The goal of these experiments was to determine 
whether TRTK-12 could block the interaction of S-100 
protein and GFAP. Specifically, we examined the effect of 
TRTK-12 on S-100's binding to GFAP, inhibition of GFAP 
assembly, and induction of GF disassembly. 
3.2. Fluorescent spectrophotometry xperiments 
In initial experiments we sought to demonstrate that 
S-100 protein, and not TRTK-12, interacts with GFAP. As 
expected from previously studies [48], addition of increas- 
ing concentration of S-100 protein to acrylodan-GFAP 
yielded a dose-dependent decrease in fluorescence inten- 
sity (Fig. 2) and a 3 nm red-shift of the fluorescence 
maximum (data not shown), indicative of S-100 protein 
Acrylodan-GFAP, 0.2 HM 
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Fig. 2. Fluorescent spectrophotometric analysis of interaction of acrylodan-GFAP with TRTK-12 or S-100 protein. Acrylodan-labelled GFAP (0.2 I.LM) 
was incubated with increasing concentrations of either TRTK-12 or S-100 protein. Fluorescence intensity is expressed as the percentage of initial values vs. 
increasing TRTK-12 or S-100 protein concentrations, as indicated. 
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associating with GFAP and this interaction inducing the 
fluorophore to relocate into a more polar environment. 
Maximal effects were obtained at a 1:1 (GFAP:S-100 
monomer) molar ratio. By contrast, addition of TRTK-12 
to acrylodan-GFAP produced only a slight decrease in the 
fluorescence intensity (Fig. 2) with no shifts of the fluores- 
cence maximum (data not shown). From these results we 
conclude that S-100, but not TRTK-12, interacts with 
GFAP. 
Fluorescent spectrophotometry was used next to exam- 
ine the capacity of TRTK-12 to perturb the interaction of 
S-100 protein and GFAP using acrylodan-labelled S-100 
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Fig. 3. Fluorescent spectrophotometric analysis of interaction of acrylodan-S-100 with TRTK-12 or GFAP. (A) Acrylodan labelled S-100 protein (0.4 txM) 
was incubated with increasing concentrations of either TRTK-12 or GFAP and relative fluorescence intensities quantified. Fluorescence intensity is 
expressed as the percentage of initial values vs. increasing TRTK-12 or GFAP concentrations, a  indicated. (B) Acrylodan labelled S-100 protein (0.4 IxM) 
was pre-incubated with 0.24, 0.78 or 2.6 I~M GFAP, as indicated, prior to addition of increasing concentrations of TRTK-12. Fluorescence intensity is 
expressed as the percent change induced by GFAP (at 0 IxM TRTK-12) vs. increasing concentrations of TRTK-12, as indicated. (C) Acrylodan labelled 
S-100 protein (0.4 I~M) was pre-incubated with 0.2, 0.4, 0.8 or 2.4 IzM TRTK-12, as indicated, prior to addition of increasing concentrations of GFAP. 
Fluorescence intensity is expressed as the percentage of initial values (at 0 tzM TRTK-12) vs. increasing GFAP concentrations, as indicated. 
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protein. Addition of increasing concentrations of TRTK-12 
to 0.4 I~M acrylodan-S-100 in the presence of free Ca 2÷ 
(= 3 IxM) produced a dose-dependent decrease in fluores- 
cence intensity (Fig. 3A) anti a slight (1-2 nm) red-shift of 
the fluorescence maximum (data not shown). These results 
indicate TRTK-12 binds S-100 protein, as was expected 
based upon our previous studies [34], and that the fluo- 
rophore has moved into a more polar environment. Maxi- 
mal effect of TRTK-12 occurred at a TRTK-12:S-100 
subunit ratio of = 1, also in accordance with previous 
results [34]. By contrast, under identical conditions, addi- 
tion of GFAP induced a dose-dependent i crease in acrylo- 
dan-S-100 fluorescence (Fig. 3A) with a pronounced blue- 
shift of the fluorescent maxima, as described previously 
[31], indicating the fluorophore's reorientation into a less 
polar environment upon binding of GFAP. Maximal en- 
hancement of fluorescence occurred at = 1 I~M GFAP 
(Fig. 3A) in agreement with the known stoichiometry (1:1) 
of GFAP:S-100 (monomer) association [31]. 
The addition of TRTK-12 to acrylodan-S-100 protein 
pre-incubated with GFAP produced a dose-dependent re- 
versal of GFAP-induced increase in fluorescence intensity; 
addition of 0.2-0.4 IxM TRTK-12 yielding a 50% de- 
crease in GFAP-dependent changes (Fig. 3B). In the con- 
verse experiment, addition of GFAP to acrylodan-S-100 
protein (0.4 IxM) that had been pre-exposed to a submolar 
equivalent of TRTK-12 (0.1-0.2 txM) induced both a 
dose-dependent i crease in fluorescence intensity (Fig. 3C) 
and blue-shift of the fluorescence maximum (data not 
shown) that were inversely related to the concentration of 
TRTK-12 present. At molar equivalent concentrations of 
TRTK-12 (vs. S-100), addition of GFAP induced only a 
limited increase in fluorescence intensity, while when an 
excess molar equivalent of TRTK-12 was present (2.4 
IxM) no increase in fluorescence intensity was observed. 
Essentially identical results; were obtained when these ex- 
periments were repeated in the presence of 100 IxM free 
Ca 2+ or = 3 ixM free Ca 2÷ and 0.1 M NaC1, except that 
under the latter condition TRTK-12 inhibited less effec- 
tively GFAP-induced changes in acrylodan-S-100 fluores- 
cence, and GFAP addition more efficaciously overcame 
TRTK-12 induced changes (data not shown). 
From these experiments we conclude that the binding of 
TRTK-12 and GFAP to S-100 is both Ca 2÷- and dose-de- 
pendent ,  saturat ing at a mo lar  ratio o f  1 
([TRTK12/GFAP]:S-100 monomer). Also, under appro- 
priate conditions, addition of either GFAP or TRTK-12 (or 
S-100) reverses changes mediated by the other 
protein/peptide on acrylodan-S-100 or (acrylodan-GFAP) 
fluorescence intensity. 
3.3. Cross- l inking exper iments 
Incubation of GFAP with the bifunctional chemical 
cross-linker DSS and subsequent SDS-PAGE analysis de- 
tected the formation of a family of low-molecular weight 
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Fig. 4. Analysis of GFAP:S-100 interaction by chemical cross-linking: 
Effect of TRTK-12. (A) GFAP (16 ~M) was incubated with S-100 
protein (6 ~M), TRTK-12 and additional dditives, as indicated, prior to 
addition of the bi-functional chemical cross-linker DSS. Samples were 
analyzed by SDS-PAGE under educing conditions and gels stained with 
Coomassie brilliant blue. Parallel samples were analyzed by immunoblot 
to confirm conjugate composition (data not shown). Small arrowhead, 
S-100 protein; small arrow, GFAP monomers (50 kDa); open arrowhead, 
GFAP:S-100 complex (60 kDa); bracket, low-molecular weight GFAP 
oligomers; large arrowhead, high-molecular weight GFAP oligomers. As 
expected cross-linked complexes > 50 kDa were dependent upon the 
presence of GFAP, and appearance of the 60 kDa GFAP:S-100 complex 
dependent upon the inclusion of Ca 2+ in reaction mixtures (data not 
shown, [31]). (B) Material migrating at the position corresponding to the 
GFAP:S-100 complex (60 kDa) was quantified by densitometry and 
results presented asthe relative intensity vs. the concentration of TRTK-12 
present. 
and high-molecular weight oligomers (Fig. 4A, lane b), 
Incubation of S-100 protein (6 I~M) with GFAP (16 IxM) 
in the presence of = 3 IxM free Ca 2+, followed by addi- 
tion of DSS and SDS-PAGE analysis identified an addi- 
tional 60 kDa GFAP:S-100 subunit complex (Fig. 4A, lane 
c) and shift in GFAP distribution from the high-molecular 
weight towards the low-molecular weight family of 
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oligomers. Addition of TRTK-12 inhibited the formation 
of this complex in a dose- and Ca2+-dependent manner, 
half-maximal inhibition occurring at = 3 p~M TRTK-12 
(Fig. 4A, lanes d-g and Fig. 4B). Concomitant with the 
decrease in the 60 kDa complex was an increase of 
high-molecular weight oligomers and decrease in low- 
molecular weight species to control values. The effects of 
S-100 protein on GFAP:GFAP complex formation were 
dependent upon the presence of S-100 protein and were 
not observed in the absence of Ca 2+ and the addition of 
TRTK-12 alone was without effect. Moreover, TRTK-12 
alone had no effect on the DSS-dependent formation of 
GFAP complexes (Fig. 4A). Western blot analysis, per- 
formed using a rabbit anti-S-100 polyclonal antiserum 
identified S-100 as a component of the 60 kDa band, as 
well as with the low-molecular weight, but not the high- 
molecular weight oligomers (data not shown; but see the 
accompanying report [57]). Addition of increasing concen- 
trations of TRTK-12 produced a concentration dependent 
decrease of the level of S-100 immunoreactivity present in 
the 60 kDa band (half-maximal inhibition occurring at = 3 
IxM) and the low-molecular weight oligomers (Fig. 4B). 
We conclude TRTK-12 functions as an effective inhibitor 
of S-100 protein dependent effects on GFAP assembly, 
presumably by disrupting the GFAP:S-100 complex and 
consistent with our hypothesis that TRTK-12 acts to mimic 
S-100 protein's endogenous binding site within the head 
domain of GFAP. 
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Fig. 5. Analysis of GFAP assembly and disassembly: effects of S-100 protein and TRTK-12. (A) GFAP (16 ixM) was assembled into intermediate 
filaments in the presence or absence of S-100 protein (16 ~M) and TRTK-12 (30 IxM), as indicated below. Completed incubation mixtures were 
centrifuged (13 000 × g) to separate 'soluble' GFAP (supernatant, s) from 'insoluble' filamentous GFAP (pellet, p) and equivalent aliquots analyzed by 
10% SDS-PAGE. Reaction mixtures contained GFAP, S-100 and/or TRTK-12 as indicated. 
Reaction type Result 
De novo assembly: 
Lanes a and b: GFAP alone. 
Lanes c and d: GFAP and S100 
Lanes e and f: GFAP, S-100 and TRTK-12. 
Reactions with preformed GFAP filaments: 
Lanes g and h: Preformed filaments plus S-100. 
Lanes i and j: Preformed filaments plus S-100 and TRTK-12. 
Two-stage reactions: 
Lanes k and 1: Filaments formed in presence of TRTK-12, with subsequent addition of S-100. 
Lanes m and n: Assembly reactions performed in presence of S-100 subsequent addition of TRTK-12. 
assembly 
assembly inhibited 
assembly 
disassembly 
disassembly inhibited 
disassembly blocked 
assembly restored 
(B) Experimental conditions were as in panel A, except hat GFAP was assembled in the presence or absence of either 8 0,M or 16 I.LM S-100 protein, and 
the indicated concentrations of TRTK-12. Stained gels were scanned ensitometrically to determine the fraction of GFAP recovered in GF pellets. The 
effect of TRTK-12 addition to GFAP assembly reactions containing S-100 is presented as the percent maximal S-100-mediated inhibition of assembly vs. 
TRTK-12 concentration. 
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Fig. 6. Viscometric analysis of TRTK-12's effect on S-100 protein-mediated inhibition of GFAP assembly. Conditions were as described in Fig. 4A, 
except hat GFAP assembly was monitored by viseometry. 
3.4. Sedimentation and viscosity assays 
The ability of TRTK-12 to block S-100's capacity to 
inhibit the assembly of GFAP and to induce GFAP IF 
disassembly was investigated further using both sedimenta- 
tion and viscosity assays. In the sedimentation assay, 
TRTK-12 blocked the inhibitory effects of S-100 on GFAP 
assembly in a concentration-dependent manner (Fig. 5A, 
lanes a- f  and Fig. 5B), half-maximal effect occurring at 
= 20 txM peptide in an assay containing both S-100 and 
GFAP at 16 I.tM. When these experiments were done with 
16 IxM GFAP and 8 ixM S-100 protein, half-maximal 
effect of TRTK-12 was observed at = 6 txM. Altogether, 
these data point to a stoichiometric effect of TRTK-12 on 
the inhibitory action of S-100 protein on GFAP assembly. 
Moreover, while the addition of S-100 protein to pre- 
formed GF produced significant ( = 60%) disassembly (Fig. 
5A, lanes g and h), simultaneous addition of S-100 protein 
together with TRTK-12 significantly reduced S-100's ca- 
pacity to mediate GF disassembly (Fig. 5A, lanes i and j). 
Finally, addition of TRTK-12 was determined to reverse 
the inhibitory effect of S-100 protein on GFAP assembly 
when added to GF formed in the presence of S-100 protein 
(Fig. 5A, lanes k and 1), and S100 protein exhibited a 
reduced capacity to disassemble GF formed in the pres- 
ence of TRTK-12 (Fig. 5A, lanes m and n). In these 
assays, TRTK-12 activity was inversely related to the 
concentration of S-100 protein present (data not shown). 
As no effect of TRTK-12 alone on GFAP assembly was 
detected in any of our analyses, we conclude the results 
obtained in experiments containing both TRTK-12 and 
S-100 protein are attributable to the blockade of S-100 
function by TRTK-12. Hence, in agreement with the re- 
suits data presented above.. TRTK-12 proved an effective 
inhibitor of S-100 protein-dependent effects on GFAP 
assembly. Presumably this effect involves the disruption of 
the GFAP:S-100 complex through the binding of a struc- 
ture homologous (i.e. TRTK-12) to the target epitope for 
S-100 contained within GFAP's head domain. 
The ability of TRTK-12 to block the inhibitory effects 
of S-100 protein on GFAP assembly was investigated by 
viscometry (Fig. 6). The addition of S-100 protein signifi- 
candy reduced the specific viscosity of GFs produced 
under assembly promoting conditions as we expected based 
upon previous results [48]. Consistent with the results 
obtained above, addition of TRTK-12 reversed S-100's 
effect with half-maximal inhibition of S-100's effect oc- 
curring between 5 and 10 I~M TRTK-12 in an assay 
containing 5 ttM S-100 and 16 IxM GFAP. 
4. Discussion 
We report herein the identification of a putative S-100 
protein target epitope contained within the head domain of 
GFAP (Table 1, Fig. 1); furthermore, we demonstrate he 
ability of an S-100 inhibitory peptide (TRTK-12; [34]), 
homologous to this epitope, to effectively disrupt GFAP:S- 
100 interactions and S-100 protein-dependent inhibition of 
GFAP assembly and induction of GF disassembly [31]. 
Hence, we conclude this domain represents the likely 
molecular target mediating S-100 protein-dependent modu- 
lation of GFAP activity. 
Several lines of evidence support his conclusion: (i) 
TRTK-12 binds S-100 but not GFAP (Fig. 2); (ii) S-100 
binds both TRTK-12 and GFAP in a Ca2+-dependent and 
saturable fashion (Fig. 3A) and the molar ratio of these 
interactions i 1; (iii) TRTK-12 reverses in a dose- and 
Ca2+-dependent fashion GFAP-dependent increases in 
acrylodan-S-100 fluorescence intensity (Fig. 3B); (iv) 
moreover, as might be expected, addition of sufficiently 
high concentrations of GFAP can reverse this effect (Fig. 
3C); (v) TRTK-12 inhibits in a dose- and Ca2+-dependent 
fashion the formation of chemically cross-linked S- 
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100:GFAP complexes (Fig. 4A, lanes a-n and Fig. 4B); 
(vi) TRTK-12 blocks S-100's inhibitory effects on GFAP 
assembly as measured in two different functional assays 
(sedimentation a d viscosity) (Figs. 5 and 6); and finally 
(vii) addition of TRTK-12 blocks S-100's ability to stimu- 
late GF disassembly (Fig. 5A). 
In all cases the interaction of TRTK-12 and GFAP with 
S-100 protein proved Ca 2 +- and dose-dependent and com- 
patible with a binding stoichiometry of 1 mol of peptide or 
protein/tool of S-100 subunit. These results are consistent 
with a model in which TRTK-12's interaction with S-100 
protein blocks the ability of S-100 protein to interact with 
other molecules, in this case GFAP. Hence, in addition to 
its ability to inhibit the interaction of S-100 protein and 
another S-100 binding protein, the actin capping protein 
CapZ [34], TRTK-12 appears to have the capacity to 
function as an effective inhibitor of S-100 protein activity 
on GFAP and GFs. 
Our data is also consistent with the molecular interac- 
tion of S-100 protein and its target proteins occurring via a 
conserved structural domain present in a variety of physio- 
logical targets. As the structure of each of these target 
domains is likely to vary in a fashion similar to the 
variability observed in our family of S-100-binding pep- 
tides [34], it will be important o determine the relative 
binding affinities of S-100 for each of the molecules 
present in this multi-component system; i.e., S-100:GFAP; 
S-100:TRTK-12; GFAP vs. S-100:TRTK-12 complex; 
TRTK-12 vs. GFAP:S-100 complex; and compare them 
with values derived from other S-100:target protein inter- 
actions. However, the availability of pleiotropic S-100 
inhibitors, such as TRTK-12, should facilitate the further 
analysis of S-100:GFAP interactions as well as S-100's 
function in vitro and in vivo. 
To comprehend at the molecular level how S-100 pro- 
tein modulates GFAP assembly and GF disassembly, a 
clear understanding of the structural features which medi- 
ate the interaction of S-100 protein and GFAP is required. 
In addition, it will be important to determine whether the 
features which promote the association of GFAP and 
S-100 protein are unique to GFAP or mediate a wide 
variety of S-100:target protein interactions. The current 
study provides information directly relevant o this objec- 
tive. Our determination that the molar ratio of S-100's 
interaction with both GFAP and TRTK-12 is 1, and that 
TRTK-12 can, in a majority of instances, displace GFAP 
from S-100 protein suggests our observations might in 
their simplest form represent the concentration- and affin- 
ity-dependent competition of molecules (TRTK-12 and 
GFAP) for a common interaction site on S-100. Based 
upon the current study we conclude that binding site is 
contained within the site we have identified in the head 
domain of GFAP. Interestingly, this region of GFAP con- 
tains the RP-box motif, which has been shown to play an 
important regulatory role in the process of GFAP poly- 
merization into GFs [56]. Thus the present studies provide 
another focal point of investigation i to the mechanisms 
regulating intermediate filament assembly. The accompa- 
nying report [57] provides further evidence for S-100 (c~ 
and [3) binding to the GFAP N-terminal head domain and 
shows that the recently recognized ability of S- 100a o (a a)  
to affect the assembly-disassembly of desmin IF [58] 
depends on S-100 protein binding to the desmin N-termi- 
nal head domain. 
The current report provides additional evidence support- 
ive of TRTK-12 capacity to function as a pleiotropic 
inhibitor of S-100 protein function. As noted, availability 
of a targeted S-100 inhibitor will assist the further charac- 
terization of S-100 protein function. In particular, it should 
prove instructive to use TRTK-12 to investigate the inter- 
action of S-100 (a and [3) with a variety of previously 
identified S-100 targets; e.g., microtubules ([17], and refer- 
ences therein), kinase substrates [ 18-21], adenylate cyclase 
[22], caldesmon regulated activities [21,23], Ca2+-induced 
Ca 2+ release [24] and the myosin-associated giant protein 
kinase twitchin [59,60]. Moreover, our recent identification 
of the actin-capping protein, CapZ, as a likely physio- 
logically relevant S-100 protein target [34] together with 
the prior association of S-100 protein with both IF [31] and 
microtubular proteins ([17], and references therein), sug- 
gest it will be important o determine whether S-100 
protein, via its interaction with components of all three 
major cytoskeletal elements, functions as a multi-faceted 
Ca2+-dependent regulator of cytoskeletal integrity in vivo. 
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